Compare WAFD & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WAFD | IBRX |
|---|---|---|
| Founded | 1917 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | N/A | N/A |
| Metric | WAFD | IBRX |
|---|---|---|
| Price | $32.05 | $1.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $31.40 | $9.71 |
| AVG Volume (30 Days) | 566.6K | ★ 13.6M |
| Earning Date | 01-15-2026 | 11-04-2025 |
| Dividend Yield | ★ 3.37% | N/A |
| EPS Growth | ★ 5.31 | N/A |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $717,732,000.00 | $82,555,000.00 |
| Revenue This Year | $8.66 | $667.18 |
| Revenue Next Year | $4.77 | $93.03 |
| P/E Ratio | $12.18 | ★ N/A |
| Revenue Growth | 1.95 | ★ 1025.95 |
| 52 Week Low | $23.75 | $1.83 |
| 52 Week High | $33.81 | $4.27 |
| Indicator | WAFD | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 40.59 |
| Support Level | $32.99 | $2.07 |
| Resistance Level | $33.25 | $2.29 |
| Average True Range (ATR) | 0.59 | 0.13 |
| MACD | -0.19 | -0.02 |
| Stochastic Oscillator | 1.63 | 5.44 |
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.